4Q 2017 Results and preliminary annual report

• 11% growth in sales revenue compared to 4Q16, 14 % y/y despite loss of our largest distributor
• Increase in sales of fCAL turbo continues
• Favorable development for Cystatin C in China

Please find the report enclosed.

The report will also be made available on www.gentian.com.

For further information, please contact:

Bård Sundrehagen CEO, Gentian Diagnostics
E-mail: bard.sundrehagen@gentian.no
Cell Phone: +47 924 14 117

Njaal Kind CFO, Gentian Diagnostics
E-mail: njaal.kind@gentian.no
Cell Phone. +47 919 06 525